149 related articles for article (PubMed ID: 29738867)
1. Pharmacoinformatics approach for the identification of Polo-like kinase-1 inhibitors from natural sources as anti-cancer agents.
AlAjmi MF; Rehman MT; Hussain A; Rather GM
Int J Biol Macromol; 2018 Sep; 116():173-181. PubMed ID: 29738867
[TBL] [Abstract][Full Text] [Related]
2. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
Kumar M; Pydi SP; Sharma S; Singh TP; Kaur P
J Mol Graph Model; 2014 Jun; 51():104-12. PubMed ID: 24879322
[TBL] [Abstract][Full Text] [Related]
3. Structural insights into the inhibitor binding and new inhibitor design to Polo-like kinase-1 Polo-box domain using computational studies.
Abdullah M; Guruprasad L
J Biomol Struct Dyn; 2019 Aug; 37(13):3410-3421. PubMed ID: 30146942
[TBL] [Abstract][Full Text] [Related]
4. Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy.
Shakil S; Baig MH; Tabrez S; Rizvi SMD; Zaidi SK; Ashraf GM; Ansari SA; Khan AAP; Al-Qahtani MH; Abuzenadah AM; Chaudhary AG
Semin Cancer Biol; 2019 Jun; 56():47-55. PubMed ID: 29122685
[TBL] [Abstract][Full Text] [Related]
5. Putative Anti-Cancer Drug Candidate Targeting the 'PLK-1-Polo-Box Domain' by High Throughput Virtual Screening: A Computational Drug Design Study.
Shakil S; Abuzinadah MF
Crit Rev Eukaryot Gene Expr; 2019; 29(3):251-261. PubMed ID: 31679235
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T
Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
[TBL] [Abstract][Full Text] [Related]
7. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Shan HM; Shi Y; Quan J
ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
[TBL] [Abstract][Full Text] [Related]
8. Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors.
Yun T; Qin T; Liu Y; Lai L
Eur J Med Chem; 2016 Nov; 124():229-236. PubMed ID: 27592392
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies.
Zhang Z; Xing X; Guan P; Song S; You G; Xia C; Liu T
Eur J Med Chem; 2021 May; 217():113314. PubMed ID: 33765606
[TBL] [Abstract][Full Text] [Related]
10. Pentafuhalol-B, a Phlorotannin from Brown Algae, Strongly Inhibits the PLK-1 Overexpression in Cancer Cells as Revealed by Computational Analysis.
Ansari WA; Rab SO; Saquib M; Sarfraz A; Hussain MK; Akhtar MS; Ahmad I; Khan MF
Molecules; 2023 Aug; 28(15):. PubMed ID: 37570823
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.
Bowers S; Truong AP; Ye M; Aubele DL; Sealy JM; Neitz RJ; Hom RK; Chan W; Dappen MS; Galemmo RA; Konradi AW; Sham HL; Zhu YL; Beroza P; Tonn G; Zhang H; Hoffman J; Motter R; Fauss D; Tanaka P; Bova MP; Ren Z; Tam D; Ruslim L; Baker J; Pandya D; Diep L; Fitzgerald K; Artis DR; Anderson JP; Bergeron M
Bioorg Med Chem Lett; 2013 May; 23(9):2743-9. PubMed ID: 23522834
[TBL] [Abstract][Full Text] [Related]
12. Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1.
Sun J; Liu HY; Xu RF; Zhu HL
Bioorg Med Chem; 2017 Dec; 25(24):6581-6588. PubMed ID: 29100732
[TBL] [Abstract][Full Text] [Related]
13. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
[TBL] [Abstract][Full Text] [Related]
14. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
Strebhardt K; Becker S; Matthess Y
Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
[TBL] [Abstract][Full Text] [Related]
15. Identification of the hot spot residues for pyridine derivative inhibitor CCT251455 and ATP substrate binding on monopolar spindle 1 (MPS1) kinase by molecular dynamic simulation.
Chen K; Duan W; Han Q; Sun X; Li W; Hu S; Wan J; Wu J; Ge Y; Liu D
J Biomol Struct Dyn; 2019 Feb; 37(3):611-622. PubMed ID: 29380674
[TBL] [Abstract][Full Text] [Related]
16. PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis.
Kumar S; Kim J
Biomed Res Int; 2015; 2015():705745. PubMed ID: 26557691
[TBL] [Abstract][Full Text] [Related]
17. In silico identification of putative bifunctional Plk1 inhibitors by integrative virtual screening and structural dynamics approach.
Shafique S; Bibi N; Rashid S
J Theor Biol; 2016 Jan; 388():72-84. PubMed ID: 26493360
[TBL] [Abstract][Full Text] [Related]
18. Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.
Chen F; Zhuo X; Qin T; Guo X; Zhang C; Lai L
Chem Biol Drug Des; 2017 May; 89(5):732-740. PubMed ID: 27882722
[TBL] [Abstract][Full Text] [Related]
19. Current assessment of polo-like kinases as anti-tumor drug targets.
Craig SN; Wyatt MD; McInnes C
Expert Opin Drug Discov; 2014 Jul; 9(7):773-89. PubMed ID: 24819909
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
Schöffski P
Oncologist; 2009 Jun; 14(6):559-70. PubMed ID: 19474163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
